NFE2L2 and colorectal carcinoma: Significantly, we for the first time demonstrated that cetuximab can promote RSL3-induced ferroptosis by markedly suppressing Nrf2/HO-1 signalling via p38 MAPK activation in KRAS mutant CRC cell lines.